In a phase I-II clinical research (LIBRETTO-001) [17], patients with RET-fused TC, comprising 143 treated and untreated MTC patients and 19 previously treated RET fusion-positive TC patients (including 2 ATC patients), were evaluated for the efficacy of selpercatinib. This evidence concerns the gene RET and medullary thyroid gland carcinoma.